Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride treatment makes the prostate look more like a healthy one.

A vaccine may prevent benign prostatic hyperplasia (BPH).

Personalized, minimally invasive treatments improve urology outcomes.

Most care for benign prostatic hyperplasia follows guidelines, but 5-α reductase inhibitors are often used incorrectly.

Long-term medication for enlarged prostate might not clearly affect the timing or outcomes of later surgery.

Some drugs may reduce prostatitis symptoms short-term with few side effects.

Alpha-blockers and Finasteride effectively manage BPH symptoms long-term.

Both dutasteride and finasteride improve urinary symptoms, but dutasteride may be better at reducing the risk of prostate surgery and sudden inability to urinate.

Combining TUSV with finasteride effectively treats recurrent hemospermia.

Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.

New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.

Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.

Older men with severe symptoms and larger prostates should focus on prevention, using finasteride and alpha-blockers to manage acute urinary retention.

Taking finasteride before surgery reduces blood loss in prostate procedures.

Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.

Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.

Finasteride effectively reduces prostate size and lowers surgery risk in men with benign prostatic hyperplasia.

The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.

Men over 50 often experience urinary issues due to prostate enlargement or bladder problems, treatable with therapies, medications, or surgery.

Cell transplantation faces challenges in genitourinary reconstruction, but alternative tissue sources and microencapsulation show promise.

5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.

Platelet-rich plasma shows promise for treating erectile dysfunction, but more research is needed.

Inhibiting testosterone 5alpha-reductase may help treat benign prostatic hyperplasia.

Alpha-blockers are the most effective and widely used treatment for lower urinary tract symptoms, with minimal side effects.

Adding platelet-rich plasma does not improve healing of certain fistulas.

Tamsulosin is a cost-effective treatment for BPH symptoms.

Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.